Search
Adding idelalisib (Zydelig®) to a standard chemotherapy regimen of bendamustine and rituximab (BR) significantly increases progression-free survival (PFS) and overall survival (OS) in patients with relapsed or treatment-resistant chronic lymphocytic leukemia (CLL) as compared with BR alone, according to new findings presented by a Memorial Sloan Kettering (MSK) investigator on behalf of his international co-investigators. Results from the phase III study were presented as part of the press program at this year’s American Society of Hematology annual meeting.
Learn how new research and clinical trials at Memorial Sloan Kettering Cancer Center (MSK) have helped 32-year-old Giancarlo Oviedo-Mori survive — and thrive — with advanced lung cancer for 15 years.
Obtenga información sobre cómo la nueva investigación y los ensayos clínicos en el Memorial Sloan Kettering Cancer Center (MSK) han ayudado a Giancarlo Oviedo-Mori, de 32 años, a sobrevivir, y prosperar, con cáncer pulmonar avanzado durante 15 años.
What proportion of cancer patients are eligible to benefit from precision oncology? There is an ongoing debate on this issue, partly due to a lack of consensus on which gene mutations are clinically actionable.
Experts at Memorial Sloan Kettering Cancer Center reviewed the research and found that whole food plant based diets are better than ketogenic diets at reducing cancer risk and helping people after cancer treatment live healthier lives.
Called NEXT, the factor plays an important role in handing over RNA to the exosome for destruction.
Learn about MSK’s visionary new cancer engineering PhD Program.
MSK researchers are learning more about how cancer cells can survive undetected for years only to return in new places. These insights will guide future therapies.
After 21 years of dedicated service, Elizabeth McCormick, MSN, RN, CENP, Senior Vice President, Chief Nursing Officer and Enid A. Haupt Chair, Department of Nursing, will retire from MSK at the end of 2021. During her tenure, Ms. McCormick transformed and ultimately redefined the role of nursing at MSK.
Researchers at Memorial Sloan Kettering are developing a new strategy for PET imaging of tumors that could result in new tools to detect and monitor prostate cancer.